Physician profile
Hope Smith
NPI 1922482587
$68,143.09
in general payments reported to CMS, 2019-2025
15 companies · $65K in 2025
The $65K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.43 · 2022: $575 · 2023: $792 · 2024: $1,609 · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Travel and Lodging: $6,991 · Food and Beverage: $5,753 · Consulting Fee: $2,500 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,096.00 |
| Travel and Lodging | $6,991.14 |
| Food and Beverage | $5,753.03 |
| Consulting Fee | $2,500.00 |
| Education | $214.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50,459.87 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $14,273.19 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $634.63 | 2022-2025 | |
| Alkermes, INC. | $592.01 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $528.91 | 2022-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $452.22 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $419.81 | 2022-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $304.72 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $111.77 | 2023-2025 | Abilify Maintena, Rexulti |
| Lundbeck LLC | $109.93 | 2022-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $76.61 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $67.35 | 2024-2025 | Qelbree |
| Corium, LLC | $55.62 | 2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $35.12 | 2022 | |
| Collegium Pharmaceutical, INC. | $21.33 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.